PTC Therapeutics (NASDAQ:PTCT – Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.42, FiscalAI reports. The business had revenue of $272.55 million during the quarter, compared to analyst estimates of $218.80 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.PTC Therapeutics’s quarterly revenue was up 43.5% compared to the same quarter last year. During the same period last year, the company earned $10.04 earnings per share.
Here are the key takeaways from PTC Therapeutics’ conference call:
- Record quarter with $273M total revenue and $226M net product revenue; management raised 2026 product revenue guidance to $750M–$850M and total revenue to $1.08B–$1.18B.
- Sephience launch accelerating—Q1 Sephience revenue was $125M (36% QoQ), U.S. starts averaging ~140/month, >90% of U.S. PKU centers have prescribed, and commercial roll?out is planned in up to 30 countries by year?end with payers covering >2/3 of the U.S. population.
- Positive 24?month PIVOT?HD interim results for votoplam: the 10 mg dose showed a ~52% slowing of disease progression vs a matched natural history cohort in Stage 2 and a favorable safety profile, supporting the Novartis?led phase III INVEST?HD (?770 pts) now enrolling.
- Vatiquinone path forward agreed with FDA: an open?label, natural?history?controlled 24?month study (?120 patients, age 7–21, primary mFARS) will be initiated to support NDA resubmission, which management says increases probability of success but requires additional data collection.
- Strong liquidity with $1.89B in cash, cash equivalents and marketable securities as of March 31, 2026, which management says supports ongoing R&D, the Sephience launch, and selective accretive business development.
PTC Therapeutics Stock Up 14.3%
PTCT stock traded up $9.20 during trading on Friday, hitting $73.69. The company had a trading volume of 5,836,355 shares, compared to its average volume of 1,252,004. The firm has a 50-day moving average price of $67.69 and a 200-day moving average price of $72.07. The stock has a market cap of $6.11 billion, a price-to-earnings ratio of 9.52 and a beta of 0.53. PTC Therapeutics has a 12 month low of $43.17 and a 12 month high of $87.50.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on PTCT
Trending Headlines about PTC Therapeutics
Here are the key news stories impacting PTC Therapeutics this week:
- Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
- Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
- Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Insider Activity at PTC Therapeutics
In other PTC Therapeutics news, EVP Lee Scott Golden sold 829 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the transaction, the executive vice president owned 79,115 shares of the company’s stock, valued at approximately $5,379,028.85. This represents a 1.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Matthew B. Klein sold 2,850 shares of the business’s stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $70.91, for a total value of $202,093.50. Following the transaction, the chief executive officer owned 394,070 shares of the company’s stock, valued at $27,943,503.70. The trade was a 0.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 126,492 shares of company stock worth $8,634,621 over the last 90 days. Insiders own 5.50% of the company’s stock.
Institutional Investors Weigh In On PTC Therapeutics
Several large investors have recently modified their holdings of PTCT. UMB Bank n.a. bought a new stake in PTC Therapeutics during the 4th quarter worth approximately $26,000. Comerica Bank increased its holdings in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares in the last quarter. IFP Advisors Inc increased its holdings in PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of PTC Therapeutics by 247.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 814 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of PTC Therapeutics by 96.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 921 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 452 shares in the last quarter.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Further Reading
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
